Skip to main content
Tiansheng Pharmaceutical Group Co.,LTD. logo

Tiansheng Pharmaceutical Group Co.,LTD. — Investor Relations & Filings

Ticker · 002872 ISIN · CNE100002QC3 LEI · 300300WMHEVMKBR2QG97 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,259 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002872

About Tiansheng Pharmaceutical Group Co.,LTD.

https://www.tszy.com.cn

Tiansheng Pharmaceutical Group Co., LTD. is a comprehensive pharmaceutical enterprise specializing in the research, development, manufacturing, and distribution of medicinal products. The company maintains a diverse portfolio encompassing traditional Chinese medicine (TCM) formulations, chemical drugs, and health supplements. Its core therapeutic focus includes cardiovascular health, respiratory conditions, and gastrointestinal disorders. Tiansheng operates an integrated supply chain that spans from the cultivation of medicinal herbs to advanced manufacturing and logistics. The company prioritizes technological innovation and stringent quality control across its production bases. By integrating modern scientific research with traditional medicinal practices, Tiansheng aims to provide effective healthcare solutions. Its infrastructure includes specialized research centers and modern production facilities designed to meet international standards for pharmaceutical safety and efficacy.

Recent filings

Filing Released Lang Actions
关于申请撤销部分其他风险警示暨继续被实施其他风险警示的进展公告
Regulatory Filings Classification · 90% confidence The document is a progress announcement concerning the application to remove certain risk warnings and the continuation of other risk warnings for the company’s securities listing. It does not contain financial statements or detailed financial data, nor is it a proxy, dividend notice, share issue, or executive certification. It is a regulatory compliance announcement under stock exchange rules, fitting the general “Regulatory Filings” category (RNS).
2026-05-22 Chinese
北京中银律师事务所关于天圣制药集团股份有限公司2025年年度股东会之法律意见书
Regulatory Filings Classification · 92% confidence The document is a legal opinion letter (法律意见书) issued by Zhong Yin Law Firm regarding the convening, procedures, attendee qualifications, and voting results of the company’s 2025 Annual General Meeting. It is primarily an attestation/certification by external counsel rather than the underlying report or a simple voting‐results announcement made by the company itself. Under the certification rule, such legal opinions or attestations should be classified as Regulatory Filings (RNS), even though it includes vote tallies.
2026-05-19 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is the formal announcement of the 2025 annual shareholders’ meeting resolutions, containing detailed vote counts and outcomes for each agenda item. It reports the official results of shareholder voting at an AGM, matching the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-19 Chinese
关于公司股票交易被实行其他风险警示相关事项的进展公告
Regulatory Filings Classification · 88% confidence The document is a formal corporate announcement concerning the status and progress of “other risk warnings” on the company’s stock by the Shenzhen Stock Exchange, the administrative penalties received, applications to remove those warnings, and ongoing disclosure obligations. It contains no financial statements or substantive analysis but is a compliance/regulatory disclosure about stock trading risk status. It does not fit specific categories like earnings release (ER), interim report (IR), management change (MANG), etc., and thus falls under general regulatory announcements.
2026-05-11 Chinese
关于举行2025年度网上业绩说明会的公告
Regulatory Filings Classification · 87% confidence The document is a regulatory notice announcing the date, time and participation details for the company’s 2025 online performance briefing (“业绩说明会”) following the disclosure of its annual report. It does not contain financial statements, actual results, or substantive presentation content itself, nor is it the full earnings release or transcript. It is an announcement of a forthcoming investor event, best classified as a general regulatory filing. Therefore, it falls under Regulatory Filings (RNS).
2026-05-11 Chinese
关于部分产品拟中选全国中成药采购联盟集中带量采购的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Tian Sheng Pharmaceutical Group Co., Ltd. regarding the proposed selection of certain products in a national centralized procurement alliance for traditional Chinese medicine. It includes product details, potential impact on the company, and risk warnings. The document is short (1000 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an announcement about procurement results and potential future contracts, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Capital Update. It is a regulatory announcement about business operations and procurement results, which fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2026-05-07 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.